|Day's Range||174.52 - 176.10|
|52 Week Range||132.39 - 176.14|
|PE Ratio (TTM)||22.48|
|Dividend & Yield||2.50 (1.43%)|
|1y Target Est||N/A|
With its $249 test to screen for 30 genes linked to eight hereditary cancers, Color Genomics Inc. has pushed to detect cancer earlier but also take price away as a barrier. Color took a big step toward those goals Monday: It said a number of health insurers — including UnitedHealthcare, part of UnitedHealth Group Inc. (UNH), Anthem Inc. (ANTM) and Blue Shield of California — will contract starting June 15 for its saliva test for cancer.
These three stocks are showing short-term gain catalysts and longer-term growth potential.
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco